New advances in mucosal vaccination.
The ICI 2013 Mucosal Vaccine Workshop presentations covered a wide range of topics, these mainly fell into three categories: (i) Understanding the interactions of host and microbes, specifically commensal pathogens and improving the antigen uptake via the (microfold cells) M cells to induce effective IgA antibody immunity at the gut mucosa; (ii) effective plant-based vaccines and (iii) development of prophylactic and therapeutic mucosal-based vaccine strategies for virus infections such as human immunodeficiency virus (HIV), influenza and human papillomavirus (HPV) associated head and neck cancers. How to improve the efficacy of oral vaccines, novel intranasal mucosal adjuvants and a unique intra-cheek delivery method were also discussed. Presenters emphasized the differences associated with systemic and mucosal vaccination, specifically, how mucosal vaccines unlike systemic delivery can induce effective immunity at the first line of defence. Collectively, the workshop provided insights into recent developments in the mucosal vaccine research field, highlighting the complexities associated with designing safe and effective mucosal vaccines.
Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia. Electronic address: Charani.Ranasinghe@anu.edu.au.
Charani
C
Ranasinghe
D000276:Adjuvants, Immunologic; D000818:Animals; D000941:Antigens / Q000276:immunology; D041981:Gastrointestinal Tract / Q000276:immunology; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D018928:Immunity, Mucosal; D009092:Mucous Membrane / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control
D000276:Adjuvants, Immunologic; D000941:Antigens; D014612:Vaccines
Autophagy; IgA; Intra-cheek delivery; M cells; Mucosal adjuvants; Mucosal vaccines; Plant-based vaccines; T cell avidity; intranasal delivery; oral delivery